Fulltext

The impact of infectious diseases consultation on the management and outcomes of Pseudomonas aeruginosa bacteraemia in adults: a retrospective cohort study

Chiong F 1 , Wasef MS 2 , Liew KC 3 , Cowan R 3 , Tsai D 4 , Lee YP 5 Show all authors , Croft L 6 , Harris O 7 , Gwini SM 8 , Athan E 3

Affiliations 

  • 1 Department of Medicine, Alice Springs Hospital, PO Box 2234, Alice Springs, NT, 0871, Australia. Fabian.Chiong@nt.gov.au
  • 2 Bankstown-Lidcombe Hospital, Sydney, Australia
  • 3 Department of Infectious Diseases, University Hospital Geelong, Geelong, Australia
  • 4 University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, Australia
  • 5 Deakin Genomic Centre, Deakin University, Geelong, Australia
  • 6 School of Life and Environmental Sciences, Deakin University, Geelong, Australia
  • 7 Australian Clinical Laboratories, Geelong, Australia
  • 8 University Hospital Geelong, Geelong, Australia
BMC Infect Dis, 2021 Jul 09;21(1):671.
PMID: 34243714 DOI: 10.1186/s12879-021-06372-5

Abstract

BACKGROUND: Pseudomonas aeruginosa bacteraemia (PAB) is associated with high mortality. The benefits of infectious diseases consultation (IDC) has been demonstrated in Staphylococcal aureus bacteraemia and other complex infections. Impact of IDC in PAB is unclear. This study aimed to evaluate the impact of IDC on the management and outcomes in patients with PAB.

METHODS: This is a retrospective cohort single-centre study from 1 November 2006 to 29 May 2019, in all adult patients admitted with first episode of PAB. Data collected included demographics, clinical management and outcomes for PAB and whether IDC occurred. In addition, 29 Pseudomonas aeruginosa (PA) stored isolates were available for Illumina whole genome sequencing to investigate if pathogen factors contributed to the mortality.

RESULTS: A total of 128 cases of PAB were identified, 71% received IDC. Patients who received IDC were less likely to receive inappropriate duration of antibiotic therapy (4.4%; vs 67.6%; p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications